Tumor Volume and Tumor Crossing of the Axial Renal Midline as Preoperative Predictors of Reduced Estimated Glomerular Filtration Rate After Robotic Partial Nephrectomy

Haruyuki Ohsugi  
Kansai Medical University

Kyojiro Akiyama  
Kansai Medical University

Hisanori Taniguchi  
Kansai Medical University

Masaaki Yanishi  
Kansai Medical University

Motohiko Sugi  
Kansai Medical University

Tadashi Matsuda  
Kansai Medical University

Hidefumi Kinoshita (✉ kinoshih@hirakata.kmu.ac.jp)  
Kansai Medical University

Research Article

**Keywords:** Tumor volume, tumor crossing, axial renal midline, glomerular filtration rate, robotic partial nephrectomy

**DOI:** https://doi.org/10.21203/rs.3.rs-538641/v1

**License:** ☝️ This work is licensed under a Creative Commons Attribution 4.0 International License.  
[Read Full License]
Abstract

The ability of nephrometry scoring systems, including the radius, exophytic/endophytic, nearness to collecting system or sinus, anterior/posterior, and location relative to polar lines (R.E.N.A.L.), to predict loss of renal function after robotic partial nephrectomy (RPN) is still controversial. Therefore, we verified which combination of factors from nephrometry scoring systems, including tumor volume, was the most significant predictor of postoperative renal function. Patients who underwent RPN for cT1 renal tumors in our hospital were reviewed retrospectively (n=163). The preoperative clinical data (estimated glomerular filtration rate [eGFR], comorbidities, and nephrometry scoring systems including R.E.N.A.L.) and perioperative outcomes were evaluated. We also calculated the tumor volume using the equation applied to an ellipsoid by three-dimensional computed tomography. The primary outcome was reduced eGFR, which was defined as an eGFR reduction of ≥20% from baseline to 6 months after RPN. Multivariate logistic regression analyses were used to evaluate the relationships between preoperative variables and reduced eGFR. Of 163 patients, 24 (14.7%) had reduced eGFR. Multivariate analyses indicated that tumor volume (cutoff value ≥14.11 cm$^3$, indicating a sphere with a diameter ≥ approximately 3 cm) and tumor crossing of the axial renal midline were independent factors for reduced eGFR (odds ratio [OR], 4.57; P=0.003 and OR, 3.21; P=0.034, respectively). Our classification system using these two factors showed a higher area under the receiver operating characteristic curve (AUC) than previous nephrometry scoring systems (AUC=0.786 vs. 0.653–0.719), and it may provide preoperative information for counseling patients about renal function after RPN.

Introduction

Partial nephrectomy (PN) is the current standard treatment for the management of small renal tumors to prevent postoperative chronic kidney disease (CKD). In particular, a warm ischemic time (WIT) within 25 minutes is considered to be associated with preventing short- and long-term loss of renal function [1]. Recent meta-analyses have shown that the WIT is significantly shorter in robotic partial nephrectomy (RPN) than in laparoscopic partial nephrectomy [2]; thus, RPN is generally accepted as a favorable procedure for preserving kidney function.

There are some nephrometry scoring systems such as the radius, exophytic/endophytic, nearness to collecting system or sinus, anterior/posterior, and location relative to polar lines (R.E.N.A.L.), preoperative aspects and dimensions used for anatomic (PADUA) classification, and diameter-axial-polar (DAP) scores for predicting surgical complexity and potential perioperative morbidity [3,4,5]. Whether these nephrometry scoring systems have the ability to predict loss of renal function after PN is still controversial [6,7]. Furthermore, some reports that used mathematical calculated scores determined from preoperative images, such as the centrality index (c-index) and tumor contact surface area, predicted that the estimated glomerular filtration rate (eGFR) decreases after PN [8,9]. However, to our knowledge, the combination of nephrometry scoring systems and mathematically calculated scores has not been evaluated for predicting renal function after RPN.
Therefore, we verified which combination of factors from the nephrometry scoring systems, including tumor volume accurately calculated by three-dimensional computed tomography (3D-CT), was the most significant predictor of reduced postoperative renal function. Finally, we described the accuracy of this new classification system including significant factors for predicting eGFR reduction compared with that of R.E.N.A.L., PADUA, and DAP scores.

Results

Patient Characteristics. The clinical patient characteristics are shown in Table 1. The median percent decrease in eGFR six months after RPN was 7.55% (IQR: 1.42–15.29%). Of 163 patients, 24 (14.7%) had an eGFR reduction of ≥ 20% from baseline to 6 months after RPN. The accurately calculated median tumor volume was 6.28 cm$^3$ (IQR: 2.70–14.68 cm$^3$). The nephrometry scores (R.E.N.A.L. and DAP scores) are shown in Table 2. The median R.E.N.A.L. score was six, and the median DAP score was five. No postoperative complications greater than Grade 3 in Clavien-Dindo Classification were observed.

Association between Reduced eGFR and Each Factor of the Nephrometry Scoring Systems including the Tumor Volume Accurately Calculated by 3D-CT. The appropriate cutoff value of tumor volume calculated by 3D-CT for predicting reduced eGFR was 14.11 cm$^3$ (sensitivity = 0.625 and specificity = 0.806) (Fig. 1a). The tumor volume factor (cutoff value ≥ 14.11 cm$^3$, indicating a sphere with a diameter ≥ approximately 3 cm) showed a higher AUC than the size factor of the DAP and R.E.N.A.L. classification systems (0.715 vs 0.547–0.636; Fig. 1b). Univariate analyses of each factor of the nephrometry scoring systems are shown in Table 3. The N and L factors of the R.E.N.A.L. system, the P factor of the DAP system, and size factors were found to be significantly associated with the outcome of interest (all P < 0.05). The number of patients with 3 points for the L factor of the R.E.N.A.L. system was the same as the number of patients with 3 points for the P factor of the DAP system (n = 41); these factors indicate the presence of a tumor crossing of the axial renal midline. These results implied that the N factor of the R.E.N.A.L. system (2 or 3 points) and the P factor of the DAP system (3 points) are significant factors for predicting reduced eGFR.

Uni- and Multivariate Analyses Predicting Reduced eGFR. Those significant nephrometry factors including tumor volume factor (cutoff value ≥ 14.11 cm$^3$) and preoperative clinical patient characteristics were investigated on uni- and multivariate analyses. The univariate analyses showed that a comorbidity of DM, the tumor volume, the N factor of the R.E.N.A.L., and the P factor of the DAP system were significantly associated with reduced eGFR (all P < 0.05, Table 4). The multivariate analysis showed that 3 points for the P factor of the DAP system (OR: 3.50, P = 0.014) and tumor volume (OR: 4.57, P = 0.003) were significant independent factors for predicting reduced eGFR (Table 4).

Accuracy of Our Classification System for Predicting Decreased Renal Function. According to the number of independent factors (3 points for the P factor of the DAP system and tumor volume), all patients were stratified into the following three groups: low-risk group (0 factors, n = 102), intermediate-risk group (1 factor, n = 39), and high-risk group (2 factors, n = 22). The classification system showed a statistically
significant trend for predicting postoperative decreases in eGFR (continuous variable) 6 months after RPN (P < 0.001; Fig. 2a) and for predicting the WIT (P < 0.001; Fig. 2b). To ascertain whether our classification system was useful for predicting postoperative reduced eGFR, we compared the predictive accuracy between our classification system and nephrometry scoring systems such as the R.E.N.A.L. score (low, intermediate, and high), PADUA score (low, intermediate, and high), and DAP sum score. Our classification system showed a higher AUC than these nephrometry scoring systems (0.786 vs. 0.653–0.719) in our cohort (Fig. 2c).

**Discussion**

The current study demonstrated that tumor volume (cutoff value $\geq 14.11 \text{ cm}^3$, indicating a sphere with a diameter $\geq$ approximately 3 cm) and 3 points for the P factor of the DAP system, indicating a tumor crossing the axial renal midline, were significant factors for predicting eGFR reduction after RPN. The simple classification system using these two factors had the best accuracy for predicting eGFR reduction after RPN compared with existing nephrometry scoring systems such as the R.E.N.A.L., DAP, and PADUA scores. Our classification system can provide prognostic information for counseling patients about renal function after RPN and assist in preoperative decision making.

To assess overall survival benefits in patients with renal cell carcinoma (RCC) after partial or radical nephrectomy, predicting both oncologic outcomes and decreased renal function to avoid chronic kidney disease is essential [12,13]. Some studies have determined that an SCr level $> 2.0 \text{ mg/dl}$ or the occurrence of stage-5 CKD is the endpoint of postoperative renal function [14,15]. However, a limitation of these endpoints is that the outcome can depend on the preoperative state. To circumvent this limitation, analysis of eGFR reduction from baseline to a point after surgery is crucial for predicting accurate postoperative renal function. General functional reduction after PN averages approximately 10% in the two-kidney and 20% in the one-kidney model [16]. Thus, we set the cutoff point for reduced eGFR to 20% with reference to a previous report [9].

Recent reports have shown that a nomogram with the sum of the R.E.N.A.L. score incorporated accurately predicts significant eGFR reduction after PN [17,18]. Therefore, the nephrometry scoring systems might be able to predict a decline in renal function after PN. Simmons et al. reported that the DAP score, which is a modified version of the R.E.N.A.L. classification and c-index, had simplified methodology and was associated with volume loss and renal function after PN. Although the cutoff value for each factor was different, similar to the DAP score including tumor diameter, axial distance from the center point, and polar distance from the midline, tumor volume, nearness to the collecting system (distance from the tumor to the collecting system), and location relative to polar lines were significantly associated with eGFR decline after RPN in this study. Among these three factors, nearness to the collecting system was not an independent factor associated with the outcome of interest. However, the distance from the tumor to the collecting system tended to be shorter as the P factor score of the DAP system increased, and it was negatively correlated with tumor volume (Supplementary Fig. 2, $R = 0.481, p < 0.001$). Thus, the two independent factors used in our classification system may also reflect proximity to the collecting system.
In complex cases, long ischemia times are required for complete tumor resection [19]. For renal function preservation, various techniques during PN have been described (e.g., off-clamp, selective/super-selective clamp, and early unclamp, or cooling techniques for hypothermia) [20,21]. We showed that our classification system was significantly correlated with the WIT (Fig. 2B); thus, our classification system might be related to the complexity of the surgery. Therefore, our classification system might help to select patients who need various surgical techniques to avoid renal insufficiency.

Our results should be interpreted with caution because of several limitations. First, this study was based on data from patients who were treated at a single center, and external validation is needed before applying the classification system to select patients. Second, the study was retrospective in design with, and the follow-up period was relatively short. Third, while perioperative variables such as the WIT and estimated blood loss were not considered, these variables are likely important influencers of postoperative renal function. However, the purpose of this study was to determine which combination of preoperative factors such as nephrometry scoring systems were best for predicting eGFR reduction. We also calculated the tumor volume assuming that each tumor was an ellipsoid. This was not a true volume, but the calculation of tumor volume is easily obtained from preoperative 3D-CT scans.

**Conclusion**

Accurate calculation of tumor volume and tumor crossing of the axial renal midline were independent predictors of eGFR reduction after RPN. Our classification system using these two factors had the best accuracy for predicting postoperative eGFR reduction when compared with previous nephrometry scoring systems such as the R.E.N.A.L., DAP, and PADUA scores.

**Methods**

Patient Selection. The medical records of 165 patients who underwent RPN for localized cT1 renal tumors with warm ischemia at Kansai Medical University Hospital between August 2014 and December 2019 were retrospectively reviewed. Patients with multiple renal tumors or a solitary kidney were excluded from this study. No patient underwent presurgical treatment with tyrosine kinase inhibitors or immune checkpoint inhibitors. All procedures were performed by experienced robotic surgeons at a single institution. Among these patients, two patients who underwent conversion to nephrectomy or open partial nephrectomy were excluded from the analysis. Ultimately, 163 patients were considered for further analyses.

Data Collection. The preoperative clinical data (sex, age, body mass index (BMI), American Society of Anesthesiologists (ASA) score, comorbidities of diabetes mellitus (DM) and hypertension (HTN), previous abdominal surgery, and antiplatelet or anticoagulant therapy), perioperative outcomes, and pathological features were evaluated. Renal function was assessed by serum creatinine (SCr) and eGFR, which was calculated using the following equation established for the Japanese population [10]:

\[
eGFR (\text{mL/min/1.73 m}^2) = 194 \times \text{Cr}^{-1.094} \times \text{age}^{-0.287} \times 0.739 \text{ for females} \quad (\text{Eq. 1})
\]

The percent reduction in
renal function was calculated with the preoperative and postoperative (6 months after RPN) eGFRs. All patients underwent preoperative 3D-CT with or without contrast. Based on the imaging findings, nephrometry scoring systems including R.E.N.A.L., PADUA, and DAP scores were evaluated with several urologists at a preoperative conference. The lengths of the horizontal axis and vertical axis were measured at the transverse plane where the tumor area was the largest (x and y, respectively), and the length of maximal z axis was measured in the coronal or sagittal plane (z). Then, the tumor volume was calculated using the following equation applied to an ellipsoid (Supplementary Fig. 1): Tumor volume \((\text{cm}^3) = \frac{4}{3} \times \pi \times (3.14) \times \frac{x}{2} \times \frac{y}{2} \times \frac{z}{2}\) (Eq. 2). The lengths of these three directions and the distance from the tumor to the collecting system were measured independently by two observers (HO and KA), each of whom was blinded to the clinical outcome.

Statistical Analysis. The primary outcome of this study was a reduced eGFR, which was defined as an eGFR reduction of \(\geq 20\%\) from baseline to 6 months after RPN. All continuous data are shown as median values and interquartile ranges (IQRs). The area under the receiver operating characteristic curve (AUC) was used to decide the cutoff value for continuous variables including tumor volume. Univariate and multivariate logistic regression analyses were used to evaluate the relationship between clinical variables and reduced eGFR. The trend of our classification system for predicting changes in renal function was examined by performing a Jonckheere–Terpstra test. The abilities of our classification systems and previous nephrometry scoring systems to predict reduced eGFR were evaluated and compared using AUC analysis. A post hoc comparison was used to compare the group means. Odds ratios (ORs) estimated from the logistic regression analyses are reported as relative risks with corresponding 95% confidence intervals (CIs). All statistical analyses were performed using EZR version 1.65 (Saitama Medical Center, Jichi, Japan) [11]. A two-sided p value < 0.05 was considered as statistically significant.

Ethics approval. All procedures performed in the present study involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the institutional review board of the Kansai Medical University Hospital, Japan (Approval No. 2020215), and informed consent was obtained from all individual patients prior to robotic partial nephrectomy.

**Abbreviations**

AML angiomyolipoma  
ASA American Society of Anesthesiologists  
AUC area under the receiver operating characteristic curve  
BMI body mass index  
CI confidence interval
CKD chronic kidney disease
DAP diameter-axial-polar
DM diabetes mellitus
eGFR estimated glomerular filtration rate
HTN hypertension
IQR interquartile range
OR odds ratio
PADUA preoperative aspects and dimensions used for anatomic
PN partial nephrectomy
RCC renal cell carcinoma
R.E.N.A.L. radius, exophytic/endophytic, nearness to collecting system or sinus, anterior/posterior, and location relative to polar lines
RPN robotic partial nephrectomy
SCr serum creatinine
WIT warm ischemia time
3D-CT three-dimensional computed tomography

**Declarations**

**Data availability**

The datasets analysed during the current study are available from the corresponding author on reasonable request.

**Author contributions**

H Ohsugi: project development, data collection, and manuscript writing. K Akiyama: data collection. H Taniguchi: data management and manuscript editing. M Yanishi and M Sugi: data management. T Matsuda: project development and study supervision. H Kinoshita: manuscript editing and study supervision.

**Competing interests**
This study was supported by the Japan Society for the Promotion of Science Grants-in-Aid of Scientific Research (KAKENHI) (Grant No. 20K16457 to H.O).

References

1. Thompson RH, et al. Every minute counts when the renal hilum is clamped during partial nephrectomy. *Eur Urol*. **58**, 340-345 (2010).

2. Choi JE, You JH, Kim DK, Rha KH, Lee SH. Comparison of perioperative outcomes between robotic and laparoscopic partial nephrectomy: a systematic review and meta-analysis. *Eur Urol*. **67**, 891-901 (2015).

3. Kutikov A, Uzzo RG. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. *J Urol*. **182**, 844-853 (2009).

4. icarra V, et al. Preoperative aspects and dimensions used for an anatomical (PADUA) classification of renal tumours in patients who are candidates for nephron-sparing surgery. *Eur Urol*. **56**, 786-793 (2009).

5. Simmons MN, et al. Diameter-axial-polar nephrometry: integration and optimization of R.E.N.A.L. and centrality index scoring systems. *J Urol*. **188**, 384-390 (2012).

6. Cha EK, et al. Preoperative radiographic parameters predict long-term renal impairment following partial nephrectomy. *World J Urol*. **31**, 817-822 (2013).

7. Buethe DD, et al. Is the R.E.N.A.L. nephrometry scoring system predictive of the functional efficacy of nephron sparing surgery in the solitary kidney? *J Urol*. **188**, 729-735 (2012).

8. Samplaski MK, Hernandez A, Gill IS, Simmons MN. C-index is associated with functional outcomes after laparoscopic partial nephrectomy. *J Urol*. **184**, 2259-2263 (2010).

9. Hsieh PF, et al. A Mathematical Method to Calculate Tumor Contact Surface Area: An Effective Parameter to Predict Renal Function after Partial Nephrectomy. *J Urol*. **196**, 33-40 (2016).

10. Matsuo S, et al. Revised equations for estimated GFR from serum creatinine in Japan. *Am J Kidney Dis*. **53**, 982-992 (2009).

11. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. *Bone Marrow Transplant*. **48**, 452-458 (2013).

12. Huang WC, et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. *Lancet Oncol*. **7**, 735-740 (2006).

13. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med*. **351**, 1296-1305 (2004).

14. Sorbellini M, et al. Prognostic nomogram for renal insufficiency after radical or partial nephrectomy. *J Urol*. **176**, 472-476 (2006).

15. Verhoest G, et al. Predictive factors of chronic kidney disease stage V after partial nephrectomy in a solitary kidney: a multi-institutional study. *Urol Oncol*. **32**, 28.e21-26 (2014).
16. Mir MC, et al. Decline in renal function after partial nephrectomy: etiology and prevention. *J Urol.* **193**, 1889-1898 (2015).

17. Martini A, et al. A Nomogram to Predict Significant Estimated Glomerular Filtration Rate Reduction After Robotic Partial Nephrectomy. *Eur Urol.* **74**, 833-839 (2018).

18. Bertolo R, Garisto J, Li J, Dagenais J, Kaouk J. Development and Internal Validation of a Nomogram for Predicting Renal Function after Partial Nephrectomy. *Eur Urol Oncol.* **2**, 106-109 (2019).

19. Huang Q, et al. A three-dimensional, anatomy-based nephrometry score to guide nephron-sparing surgery for renal sinus tumors. *Cancer.* **126**, Suppl 9:2062-2072 (2020).

20. Cacciamani GE, et al. Impact of Renal Hilar Control on Outcomes of Robotic Partial Nephrectomy: Systematic Review and Cumulative Meta-analysis. *Eur Urol Focus.* **5**, 619-635 (2019).

21. Ramirez D, Caputo PA, Krishnan J, Zargar H, Kaouk JH. Robot-assisted partial nephrectomy with intracorporeal renal hypothermia using ice slush: step-by-step technique and matched comparison with warm ischaemia. *BJU Int.* **117**, 531-536 (2016).

**Tables**
Table 1.
Clinical patient characteristics.

| Variables                          |          |
|------------------------------------|----------|
| N                                  | 163      |
| Age, years, median (IQR)           | 66 (56 - 73) |
| Sex, n (%)                         |          |
| Female                             | 50 (30.7) |
| Male                               | 113 (69.3) |
| BMI, kg/m², median (IQR)           | 23.6 (21.9 - 25.6) |
| ASA, n (%)                         |          |
| 1                                  | 34 (20.9) |
| 2                                  | 117 (71.8) |
| 3                                  | 12 (7.4) |
| Preoperative SCr, mg/dl, median (IQR) | 0.80 (0.67 - 0.98) |
| Preoperative eGFR, ml/min/1.73 m², median (IQR) | 70.0 (57.0 - 82.5) |
| Preoperative eGFR<60, n (%)         | 47 (28.8) |
| Comorbidity of DM                  | 30 (18.4) |
| Comorbidity of HTN                 | 75 (46.0) |
| Previous abdominal surgery          | 52 (31.9) |
| Antiplatelet or anticoagulant therapy | 24 (14.7) |
| Tumor diameter, cm, median (IQR)   | 2.5 (1.95 - 3.35) |
| Tumor volume, cm³, median (IQR)    | 6.28 (2.70 - 14.68) |
| Distance from the tumor to the collecting system, mm, median (IQR) | 14 (8 - 22) |
| Approach, n (%)                    |          |
| Intraperitoneal                    | 99 (60.7) |
| Retroperitoneal                    | 64 (39.3) |
| Surgical side, n (%)               |          |
| Right                              | 87 (53.4) |
| Left                               | 76 (46.6) |
| Pathological subtype, n (%)   |       |
|------------------------------|-------|
| Clear cell RCC              | 119 (73.0) |
| Chromophobe RCC             | 14 (8.6)     |
| Papillary RCC               | 9 (5.5)      |
| Clear cell papillary RCC    | 4 (2.5)      |
| Benign neoplasm (AML or Oncocytoma) | 9 (5.5) |
| Others                      | 8 (5.0)       |

| Pathological T stage, n (%) |       |
|---------------------------|-------|
| pT1a                      | 121 (74.2)    |
| pT1b                      | 12 (7.4)      |
| pT2                       | 0 (0.0)        |
| pT3a                      | 20 (12.3)     |
| Indeterminable            | 10 (6.1)      |

| WIT, second, median (IQR)  | 1149 (883 - 1456) |
|----------------------------|------------------|
| Estimated blood loss, ml, median (IQR) | 100 (31 - 200) |
| Postoperative eGFR decrease, %, median (IQR) | 7.55 (1.42 - 15.29) |
| Postoperative eGFR decrease greater than 20%, n (%) | 24 (14.7) |

IQR, interquartile range; BMI, body mass index; ASA, American Society of Anesthesiologists; SCr, serum creatinine; eGFR, estimated glomerular filtration rate; DM, diabetes mellitus; HTN, hypertension; RCC, renal cell carcinoma; AML, angiomyolipoma; WIT, warm ischemia time.
| Variables                                      |   |
|-----------------------------------------------|---|
| N, (%)                                        | 163|
| R.E.N.A.L. score, median (IQR)                | 6 (5 - 7)|
| R.                                            |   |
| 1                                             | 142 (87.1)|
| 2                                             | 21 (12.9)|
| E.                                            |   |
| 1                                             | 58 (35.6)|
| 2                                             | 88 (54.0)|
| 3                                             | 17 (10.4)|
| N.                                            |   |
| 1                                             | 118 (72.4)|
| 2                                             | 19 (11.7)|
| 3                                             | 26 (16.0)|
| A.                                            | x  |
| a                                             | 28 (17.2)|
| p                                             | 60 (36.8)|
| L.                                            |   |
| 1                                             | 72 (44.2)|
| 2                                             | 50 (30.7)|
| 3                                             | 41 (25.2)|
| R.E.N.A.L. score risk categorization, n (%)   |   |
| Low (4-6)                                     | 100 (61.3)|
| Intermediate (7-9)                            | 52 (31.9)|
| High (≥10)                                    | 11 (6.7)|
| DAP score, median (IQR)                       | 5 (4 - 6)|
| Diameter                                      |   |
| 1                                             | 72 (44.2)|
| 2                                             | 81 (49.7)|
| 3                                             | 10 (6.1)|
| Axial                                         |   |
| 1                                             | 61 (37.4)|
| 2                                             | 69 (42.3)|
| 3                                             | 33 (20.2)|
Table 3.

Univariate analysis of each factor of nephrometry scores for predicting postoperative eGFR decrease.

| Variable                  | Univariate analysis | P value |
|---------------------------|---------------------|---------|
| R.E.N.A.L.-R. (1 vs. 2)   | 2.02 (0.66–6.17)    | 0.215   |
| R.E.N.A.L.-E. (1 vs. 2)   | 2.54 (0.88–7.32)    | 0.085   |
| R.E.N.A.L.-E. (1 vs. 3)   | 1.41 (0.25–8.03)    | 0.696   |
| R.E.N.A.L.-N. (1 vs. 2)   | 3.47 (1.05–11.50)   | 0.041   |
| R.E.N.A.L.-N. (1 vs. 3)   | 4.32 (1.53–12.20)   | 0.006   |
| R.E.N.A.L.-A. (x vs. a)   | 0.56 (0.18–1.82)    | 0.338   |
| R.E.N.A.L.-A. (x vs. p)   | 0.56 (0.18–1.73)    | 0.317   |
| R.E.N.A.L.-L. (1 vs. 2)   | 0.59 (0.15–2.41)    | 0.465   |
| R.E.N.A.L.-L. (1 vs. 3)   | 4.81 (1.75–13.20)   | 0.002   |
| DAP-Diameter (1 vs. 2)    | 3.56 (1.24–10.20)   | 0.018   |
| DAP-Diameter (1 vs. 3)    | 3.35 (0.56–20.20)   | 0.187   |
| DAP-Axial (1 vs. 2)       | 1.74 (0.60–5.02)    | 0.307   |
| DAP-Axial (1 vs. 3)       | 2.47 (0.75–8.08)    | 0.135   |
| DAP-Polar (1 vs. 2)       | 1.24 (0.34–4.52)    | 0.745   |
| DAP-Polar (1 vs. 3)       | 6.43 (2.10–19.6)    | 0.001   |

R.E.N.A.L., Radius, exophytic/endophytic, nearness to collecting system or sinus, anterior/posterior, and location relative to polar lines; DAP, Diameter-Axial-Polar; OR, Odds ratio; CI, confident interval.
Table 4.
Univariate and multivariate analysis of preoperative clinical factors for predicting postoperative eGFR decrease.

| Variables                                      | Univariate analysis | Multivariate analysis* |
|------------------------------------------------|---------------------|------------------------|
|                                                 | OR (95% CI)         | P value                | OR (95% CI)         | P value |
| Age, years (<75 vs. ≥75)                        | 0.48 (0.13–1.71)    | 0.255 -                | -                   | -       |
| Sex (female vs. male)                           | 1.39 (0.52–3.74)    | 0.515 -                | -                   | -       |
| BMI, kg/m² (<25 vs. ≥25)                        | 1.25 (0.51–3.08)    | 0.623 -                | -                   | -       |
| Preoperative eGFR, ml/min/1.73m² (≥60 vs. <60)  | 1.02 (0.39–2.65)    | 0.969 -                | -                   | -       |
| DM (absent vs. present)                         | 2.66 (1.01–6.97)    | 0.047 -                | -                   | -       |
| HTN (absent vs. present)                        | 1.21 (0.51–2.87)    | 0.672 -                | -                   | -       |
| Antiplatelet of anticoagulant therapy (absent vs. present) | 0.48 (0.11–2.21)    | 0.348 -                | -                   | -       |
| Previous abdominal surgery (absent vs. present) | 0.67 (0.25–1.81)    | 0.434 -                | -                   | -       |
| N factor in R.E.N.A.L. (1 vs. 2/3)              | 3.95 (1.61–9.67)    | 0.003 -                | -                   | -       |
| P factor in DAP (1/2 vs. 3)                     | 5.81 (2.33–14.50)   | <0.001 3.50 (1.30–9.46)| 0.014               |
| Tumor volume, cm³ (<14.11 vs. ≥14.11)          | 6.91 (2.74–17.50)   | <0.001 4.57 (1.69–12.30)| 0.003               |

BMI, body mass index; eGFR, estimated glomerular filtration rate; DM, diabetes mellitus; HTN, hypertension; R.E.N.A.L., Radius, exophytic/endophytic, nearness to collecting system or sinus, anterior/posterior, and location relative to polar lines; DAP, Diameter-Axial-Polar; OR, odds ratio; CI, confidence interval.

*Backward step-down selection was used.

Figures
Figure 1

a Receiver operating characteristic curve of tumor volume and cutoff value for predicting eGFR reduction of $\geq 20\%$. b Comparison of the AUC values of the tumor volume (cut off value $\geq 14.11 \text{ cm}^3$), D factor of the DAP system, and R factor of the R.E.N.A.L. system for predicting eGFR reduction of $\geq 20\%$. AUC area under the receiver operating characteristic curve, DAP diameter-axial-polar, R.E.N.A.L. radius, exophytic/endophytic, nearness to collecting system or sinus, anterior/posterior, and location relative to polar lines
Figure 2

a Postoperative eGFR decrease (continuous variable) with our classification system. b Intraoperative WIT with our classification system. c Comparison of the AUCs of our classification system, the DAP sum score, the R.E.N.A.L. score, and the PADUA score for predicting eGFR reduction of ≥20%. AUC area under the receiver operating characteristic curve, DAP diameter-axial-polar, eGFR estimated glomerular filtration rate, PADUA preoperative aspects and dimensions used for anatomic, R.E.N.A.L. radius,
exophytic/endophytic, nearness to collecting system or sinus, anterior/posterior, and location relative to polar lines, WIT warm ischemic time

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryInformation.pdf](https://example.com/SupplementaryInformation.pdf)